Innovating Works

COVANCE

Desconocido
IDERHA: Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage IDERHA will address the key obstacles to achieving appropriate access, sharing, use and reuse of lung cancer data, and thus enable enhanced...
2023-05-10 - 2028-03-31 | Financiado
imSAVAR: Immune Safety Avatar nonclinical mimicking of the immune system effects of immunomodulatory therapi... LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy saf...
2019-11-18 - 2025-11-30 | Financiado
ConcePTION: Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and... LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about...
2019-05-06 - 2024-12-31 | Financiado
PIONEER: Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage Prostate Cancer (PCa) is the second leading cause of cancer, among men in Europe. There are currently major unmet needs in this field, such...
2018-06-14 - 2023-10-31 | Financiado
PARADIGM: Patients Active in Research and Dialogues for an Improved Generation of Medicines Advancing meaning... LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage PARADIGM will provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engage...
2018-06-04 - 2020-11-30 | Financiado
Smart-4-Fabry: Smart multifunctional GLA nanoformulation for Fabry disease LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un H2020: H2020-NMBP-2016-2017 Lysosomal storage disorders (LSD) diseases are a group of rare diseases that currently lack a definitive cure. LSD incidence is about 1:5,00...
2016-11-22 - 2020-12-31 | Financiado
SCR&TOX: Stem Cells for Relevant Efficient Extended and Normalized Toxicology LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED participó en un FP7: In the development of products for use by humans it is vital to identify compounds with toxic properties at an early stage of their developm...
Financiado
EUROCALIN: EUROpean consortium for antiCALINs as next generation high affinity protein therapeutics The consortium aims to develop and produce an Anticalin, a member of a novel high-affinity scaffold derived from the lipocalin protein famil...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.